Видео с ютуба Functionally High-Risk Myeloma

Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T...

The impact of functionally high-risk disease in patients with R/R myeloma receiving late-line CAR-T

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8

Defining Functional High-Risk Myeloma & Why Its Important | Barry Paul, MD & Todd Kennedy | #ASH25

Functional High-Risk Disease at Relapse | Katja Weisel, MD | #IMS2025

Functional High-Risk Myeloma:CAR-T Optimizes Outcomes at Relapse | Rahul Banerjee, MD | #IMS2025

The impact of induction therapy on outcomes for patients with functional high-risk myeloma

The Key Traits of High-Risk and Functional High-Risk Multiple Myeloma Explained

Predicting and preventing early relapse in patients with newly diagnosed multiple myeloma

Validation of a novel multiple myeloma early relapse score within the WBMT global study

Cilta-cel versus SoC in functionally high-risk myeloma with one prior therapy

CARTITUDE-4 Subgroup Analysis of Functional High-Risk Patients | Luciano Costa, MD | EHA 2024

Cilta-cel vs standard of care in functional high-risk myeloma: findings from CARTITUDE-4

What does it mean to have functional high-risk multiple myeloma?

Managing patients with difficult to treat multiple myeloma

The importance of imaging for patients with high-risk disease

An analysis on patients with high-risk multiple myeloma

Real-world treatment patterns & outcomes of functional high-risk myeloma

Real world outcome for high-risk NDMM